Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Daré Bioscience stock | $1.28

Learn how to easily invest in Daré Bioscience stock.

Daré Bioscience, Inc
NASDAQ: DARE - USD
BIOTECHNOLOGY
$1.62
+$0.08 (+5.13%)

Daré Bioscience, Inc is a biotechnology business based in the US. Daré Bioscience shares (DARE) are listed on the NASDAQ and all prices are listed in US Dollars. Daré Bioscience employs 16 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Daré Bioscience

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – DARE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Daré Bioscience stock price (NASDAQ: DARE)

Use our graph to track the performance of DARE stocks over time.

Daré Bioscience shares at a glance

Information last updated 2021-07-31.
Latest market close$1.28
52-week range$0.94 - $3.01
50-day moving average $1.55
200-day moving average $1.72
Wall St. target price$5.40
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.05

Buy Daré Bioscience shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Daré Bioscience stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Daré Bioscience price performance over time

Historical closes compared with the close of $1.28 from 2021-05-28

1 week (2021-07-22) N/A
1 month (2021-07-02) -18.99%
3 months (2021-04-30) -15.23%
6 months (2021-01-29) N/A
1 year (2020-07-29) N/A
2 years (2019-07-29) N/A
3 years (2018-07-29) N/A
5 years (2016-07-29) N/A

Daré Bioscience financials

Gross profit TTM $-83,333
Return on assets TTM -185.95%
Return on equity TTM -941.6%
Profit margin 0%
Book value $0.07
Market capitalisation $76 million

TTM: trailing 12 months

Shorting Daré Bioscience shares

There are currently 5.3 million Daré Bioscience shares held short by investors – that's known as Daré Bioscience's "short interest". This figure is 126.3% up from 2.3 million last month.

There are a few different ways that this level of interest in shorting Daré Bioscience shares can be evaluated.

Daré Bioscience's "short interest ratio" (SIR)

Daré Bioscience's "short interest ratio" (SIR) is the quantity of Daré Bioscience shares currently shorted divided by the average quantity of Daré Bioscience shares traded daily (recently around 19.5 million). Daré Bioscience's SIR currently stands at 0.27. In other words for every 100,000 Daré Bioscience shares traded daily on the market, roughly 270 shares are currently held short.

However Daré Bioscience's short interest can also be evaluated against the total number of Daré Bioscience shares, or, against the total number of tradable Daré Bioscience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Daré Bioscience's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Daré Bioscience shares in existence, roughly 110 shares are currently held short) or 0.1101% of the tradable shares (for every 100,000 tradable Daré Bioscience shares, roughly 110 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Daré Bioscience.

Find out more about how you can short Daré Bioscience stock.

Daré Bioscience share dividends

We're not expecting Daré Bioscience to pay a dividend over the next 12 months.

Have Daré Bioscience's shares ever split?

Daré Bioscience's shares were split on a 1:10 basis on 19 July 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Daré Bioscience shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Daré Bioscience shares which in turn could have impacted Daré Bioscience's share price.

Daré Bioscience share price volatility

Over the last 12 months, Daré Bioscience's shares have ranged in value from as little as $0.9447 up to $3.0103. A popular way to gauge a stock's volatility is its "beta".

DARE.US volatility(beta: 1.52)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Daré Bioscience's is 1.5211. This would suggest that Daré Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Daré Bioscience overview

Daré Bioscience, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.

Frequently asked questions

What percentage of Daré Bioscience is owned by insiders or institutions?
Currently 5.567% of Daré Bioscience shares are held by insiders and 7.374% by institutions.
How many people work for Daré Bioscience?
Latest data suggests 16 work at Daré Bioscience.
When does the fiscal year end for Daré Bioscience?
Daré Bioscience's fiscal year ends in December.
Where is Daré Bioscience based?
Daré Bioscience's address is: 3655 Nobel Drive, San Diego, CA, United States, 92122
What is Daré Bioscience's ISIN number?
Daré Bioscience's international securities identification number is: US23666P1012
What is Daré Bioscience's CUSIP number?
Daré Bioscience's Committee on Uniform Securities Identification Procedures number is: 15708Q105

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site